Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 26, Issue 3, Pages 353-365
Publisher
Baishideng Publishing Group Inc.
Online
2020-01-15
DOI
10.3748/wjg.v26.i3.353
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
- (2019) Emanuel Raschi et al. Targeted Oncology
- Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of the literature
- (2019) Yudai Koya et al. HEPATOLOGY RESEARCH
- Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis
- (2019) Masashi Kono et al. INTERNAL MEDICINE
- Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports
- (2019) Takumi Onoyama et al. ENDOSCOPY
- Three cases of immune cholangitis related to anti–programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer
- (2019) Maxime Fouchard et al. EUROPEAN JOURNAL OF CANCER
- Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma
- (2019) Andreea Cǎlugǎreanu et al. Immunotherapy
- Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature
- (2019) Koji Sawada et al. INTERNAL MEDICINE
- Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy
- (2019) Yoh Zen et al. SEMINARS IN DIAGNOSTIC PATHOLOGY
- Immune-related adverse reactions in the hepatobiliary system: Second generation checkpoint inhibitors highlight diverse histological changes
- (2019) Yoh Zen et al. HISTOPATHOLOGY
- Nivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression
- (2019) Brady Anderson et al. Journal of Thoracic Oncology
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer
- (2018) Naosuke Kuraoka et al. ENDOSCOPY
- Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy
- (2018) C Hamoir et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non–Small Cell Lung Cancer
- (2018) Jang Ho Cho et al. Journal of Thoracic Oncology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
- (2018) Julie R. Brahmer et al. Journal of Oncology Practice
- Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis
- (2018) Kohei Ogawa et al. HEPATOLOGY
- Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab
- (2018) Shoko Noda-Narita et al. EUROPEAN JOURNAL OF CANCER
- An Original Case of an Association of Eosinophilic Fasciitis with Cholangitis Induced by Nivolumab
- (2018) Erwan Le Tallec et al. Journal of Thoracic Oncology
- Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
- (2017) Hisato Kawakami et al. INVESTIGATIONAL NEW DRUGS
- A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event
- (2017) Francesco Gelsomino et al. INVESTIGATIONAL NEW DRUGS
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury.
- (2016) F. Gelsomino et al. ANNALS OF ONCOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis
- (2015) Gui-Qi Zhu et al. Oncotarget
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search